Biosimilars of adalimumab: the upcoming challenge in IBD

Autor:	Giulia Roda, Mariangela Allocca, Silvio Danese, Gionata Fiorino, Federica Furfaro, Marjorie Argollo, Laurent Peyrin-Biroulet, Daniela Gilardi, Carmen Correale, Laura Loy
Přispěvatelé:	Fiorino, G, Gilardi, D, Correale, C, Furfaro, F, Roda, G, Loy, L, Argollo, M, Allocca, M, Peyrin-Biroulet, L, Danese, S
Rok vydání:	2019
Předmět:	0301 basic medicine medicine.medical_specialty Clinical Biochemistry Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Drug Discovery Adalimumab Medicine Humans Intensive care medicine Biosimilar Pharmaceuticals health care economics and organizations Pharmacology Crohn's disease Clinical Trials as Topic business.industry Antibodies Monoclonal Biosimilar medicine.disease Inflammatory Bowel Diseases Ulcerative colitis Infliximab Cost savings 030104 developmental biology 030220 oncology & carcinogenesis business medicine.drug Half-Life
Zdroj:	Expert opinion on biological therapy. 19(10)
ISSN:	1744-7682
Popis:	Introduction: Biosimilars represent great potential in cost saving and re-investment opportunities in healthcare and allow patients greater access to effective mAbs. Infliximab biosimilars are succ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::265da9d108ad42084612508f3cd2922f https://pubmed.ncbi.nlm.nih.gov/30601098 Zobrazit plný text záznamu